已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial

医学 皮塔伐他汀 内科学 人类免疫缺陷病毒(HIV) 心脏病学 病毒学 他汀类
作者
Márton Kolossváry,Samuel R Schnittman,Markella V. Zanni,Kathleen V. Fitch,Carl J. Fichtenbaum,Judith A. Aberg,Gerald S. Bloomfield,Carlos Malvestutto,Judith S. Currier,Marissa R Diggs,Christopher R. deFilippi,Allison Ross Eckard,Adrián Curran,Murat Centinbas,Ruslan I. Sadreyev,Borek Foldyna,Thomas Mayrhofer,Júlia Karády,Jana Taron,Sara McCallum
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:10 (3): 254-254 被引量:17
标识
DOI:10.1001/jamacardio.2024.4115
摘要

Importance: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown. Objective: To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH). Design, Setting, and Participants: This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial. Participants underwent coronary computed tomography angiography (CTA), plasma protein analysis, and transcriptomic analysis at baseline and 2-year follow-up. The trial enrolled PWH from April 2015 to February 2018 at 31 US research sites. PWH without known cardiovascular diseases taking antiretroviral therapy and with low to moderate 10-year cardiovascular risk were eligible. Data analyses were conducted from October 2023 to February 2024. Intervention: Oral pitavastatin calcium, 4 mg per day. Main Outcomes and Measures: Relative change in plasma proteomics, transcriptomics, and noncalcified plaque volume among those receiving treatment vs placebo. Results: Among 558 individuals (mean [SD] age, 51 [6] years; 455 male [82%]) included in the proteomics assessment, 272 (48.7%) received pitavastatin and 286 (51.3%) received placebo. After adjusting for false discovery rates, pitavastatin increased abundance of procollagen C-endopeptidase enhancer 1 (PCOLCE), neuropilin 1 (NRP-1), major histocompatibility complex class I polypeptide-related sequence A (MIC-A) and B (MIC-B), and decreased abundance of tissue factor pathway inhibitor (TFPI), tumor necrosis factor ligand superfamily member 10 (TRAIL), angiopoietin-related protein 3 (ANGPTL3), and mannose-binding protein C (MBL2). Among these proteins, the association of pitavastatin with PCOLCE (a rate-limiting enzyme of collagen deposition) was greatest, with an effect size of 24.3% (95% CI, 18.0%-30.8%; P < .001). In a transcriptomic analysis, individual collagen genes and collagen gene sets showed increased expression. Among the 195 individuals with plaque at baseline (88 [45.1%] taking pitavastatin, 107 [54.9%] taking placebo), changes in NCP volume were most strongly associated with changes in PCOLCE (%change NCP volume/log2-fold change = -31.9%; 95% CI, -42.9% to -18.7%; P < .001), independent of changes in LDL-C level. Increases in PCOLCE related most strongly to change in the fibro-fatty (<130 Hounsfield units) component of NCP (%change fibro-fatty volume/log2-fold change = -38.5%; 95% CI, -58.1% to -9.7%; P = .01) with a directionally opposite, although nonsignificant, increase in calcified plaque (%change calcified volume/log2-fold change = 34.4%; 95% CI, -7.9% to 96.2%; P = .12). Conclusions and Relevance: Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions. Trial Registration: ClinicalTrials.gov Identifier: NCT02344290.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
三块石头发布了新的文献求助10
刚刚
科研小哥的应助被寤念采纳,获得10
3秒前
alex发布了新的文献求助10
3秒前
alex发布了新的文献求助10
3秒前
alex发布了新的文献求助10
3秒前
jinlin完成签到,获得积分10
4秒前
木木完成签到 ,获得积分10
4秒前
5秒前
小何完成签到,获得积分10
8秒前
花花酱完成签到 ,获得积分10
9秒前
我姓张发布了新的文献求助10
9秒前
淡淡的代芙完成签到,获得积分10
10秒前
11秒前
JamesPei的应助被俏皮以旋采纳,获得10
11秒前
12秒前
愉快的妙竹完成签到 ,获得积分10
13秒前
句号关注了科研通微信公众号
13秒前
罗非鱼发布了新的文献求助10
14秒前
15秒前
乐乐完成签到 ,获得积分10
15秒前
15秒前
动听衬衫发布了新的文献求助10
16秒前
我姓张完成签到,获得积分10
17秒前
SciGPT的应助被罗非鱼采纳,获得10
19秒前
李林高完成签到 ,获得积分10
20秒前
金凤发布了新的文献求助10
20秒前
墨墨完成签到 ,获得积分10
20秒前
23秒前
张六六完成签到,获得积分10
25秒前
26秒前
26秒前
CipherSage的应助被OK采纳,获得10
27秒前
28秒前
天天快乐的应助被00hello00采纳,获得10
29秒前
29秒前
29秒前
NexusExplorer的应助被gsgg采纳,获得10
30秒前
华仔的应助被夏侯乌采纳,获得10
35秒前
35秒前
勤奋的含蕾完成签到 ,获得积分10
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184619
求助须知:如何正确求助?哪些是违规求助? 9573576
关于积分的说明 21832380
捐赠科研通 7781845
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003